Abstract
The treatments for pancreatic carcinoma seem to be inadequate compared with other malignancies even at present, the rate of resectability is low compared with other malignancies. Therefore, the role of chemotherapy is important especially for inoperable patients with pancreatic carcinoma. The first line of chemotherapy for pancreatic carcinoma is gemcitabine, which has been approved for use. This year, TS-1 was also approved as one of the anticancer drugs for pancreatic carcinoma. In this manuscript, the present status of anticancer drugs for pancreatic carcinoma including trials of combination therapy of anticancer drugs is discussed.
